Gonorrhea Treatment
For uncomplicated gonorrhea, treat with ceftriaxone 500 mg intramuscularly as a single dose, plus doxycycline 100 mg orally twice daily for 7 days if chlamydial coinfection has not been excluded. This represents the most current evidence-based approach that balances treatment efficacy with antimicrobial stewardship concerns 1, 2.
First-Line Recommended Regimen
The treatment landscape has evolved significantly from earlier dual-therapy recommendations. While older guidelines recommended ceftriaxone 250 mg IM plus azithromycin 1 g orally 3, the current standard is ceftriaxone 500 mg IM as monotherapy for gonorrhea, with doxycycline added only for presumptive chlamydia treatment 1, 2.
Key Points:
- Ceftriaxone 500 mg IM once for urogenital, anorectal, and pharyngeal gonorrhea
- Add doxycycline 100 mg PO twice daily for 7 days if chlamydia has not been ruled out
- This dose increase from 250 mg to 500 mg reflects updated pharmacokinetic/pharmacodynamic data and provides a safety margin against emerging resistance 1, 2
Rationale for Current Approach:
The shift away from routine azithromycin dual therapy stems from antimicrobial stewardship concerns and rapidly rising azithromycin resistance (nearly 5% of isolates with elevated MICs by 2018) 1. Meanwhile, ceftriaxone MICs have remained stable in the United States, with <0.1% showing alert values 1. The higher 500 mg dose maintains efficacy while minimizing resistance pressure on azithromycin and other antimicrobials 2.
Alternative Regimens
If Ceftriaxone is Unavailable:
Cefixime 400 mg orally once PLUS azithromycin 1 g orally once (or doxycycline 100 mg twice daily for 7 days) PLUS test-of-cure in 1 week 3.
Critical caveat: Cefixime is no longer first-line because it provides lower and less sustained bactericidal levels than ceftriaxone and has limited efficacy for pharyngeal gonorrhea 3. Rising cefixime MICs, particularly in the Western U.S. and among men who have sex with men, indicate early resistance development 3.
If Severe Cephalosporin Allergy:
Azithromycin 2 g orally once PLUS mandatory test-of-cure in 1 week 3.
This is the only viable oral alternative for patients who cannot receive cephalosporins, though it causes significant gastrointestinal distress and has suboptimal efficacy compared to ceftriaxone 3.
Historical Alternatives (No Longer Recommended):
- Quinolones (ciprofloxacin, ofloxacin, levofloxacin): Widespread resistance makes these unsuitable for empiric therapy 4, 5, 4
- Spectinomycin 2 g IM: Expensive, injectable, and only 52% effective for pharyngeal infections 6, 4. May be considered in consultation with infectious disease specialists for patients with cephalosporin and azithromycin contraindications
Site-Specific Considerations
Pharyngeal Gonorrhea:
The pharynx is the most challenging site to treat and the most common location for treatment failures 7, 8. Ceftriaxone 500 mg IM remains the only reliably effective option for pharyngeal infection 7, 1.
- Cefixime has limited pharyngeal efficacy 3
- Gentamicin and spectinomycin have poor pharyngeal efficacy (only 20% cure rate with gentamicin in one study) 7
- In a recent trial, cefixime 800 mg plus doxycycline failed to achieve non-inferiority to ceftriaxone plus azithromycin specifically due to pharyngeal treatment failures 8
Urogenital and Rectal Gonorrhea:
Both ceftriaxone 500 mg IM and alternative regimens show high efficacy (>95%) for these sites 1, 9. The cefixime-doxycycline combination demonstrated 100% efficacy for urogenital and rectal infections, despite pharyngeal failures 8.
Treatment Failure Management
If a patient has persistent symptoms or positive test after recommended treatment:
- Obtain culture with antimicrobial susceptibility testing (not just NAAT) 3
- Report to local/state health department within 24 hours 3
- Consult infectious disease specialist or CDC (404-639-8659) 3
- Consider treatment with gentamicin 240 mg IM plus azithromycin 2 g orally 7, 1
- Perform test-of-cure 1 week after re-treatment 3
- Evaluate and treat sex partners from preceding 60 days 3
European guidelines suggest additional options including ceftriaxone 1 g IM with azithromycin 2 g, spectinomycin 2 g IM with azithromycin 2 g, or ertapenem 1 g IM for 3 days 7, 9.
Critical Pitfalls to Avoid
Do not use quinolones empirically: Resistance is widespread, particularly among MSM and in California, Hawaii, and internationally acquired infections 4, 5, 4
Do not routinely add azithromycin for gonorrhea alone: Current guidelines reserve azithromycin for chlamydia coinfection only, not as dual therapy for gonorrhea 1, 2
Do not skip test-of-cure when using alternative regimens: Mandatory for cefixime-based regimens and azithromycin monotherapy 3
Do not assume urogenital treatment success predicts pharyngeal cure: The pharynx requires specific consideration and higher-dose ceftriaxone 7, 8
Do not use ceftriaxone with calcium-containing solutions in neonates: Fatal precipitations have occurred 10
Special Populations
Pregnancy:
Use ceftriaxone 500 mg IM. Avoid quinolones and tetracyclines. If cephalosporin allergy exists, spectinomycin 2 g IM may be considered, though efficacy data are limited 6.
Neonates:
Contraindicated to use ceftriaxone in premature neonates or those requiring calcium-containing IV solutions due to precipitation risk 10. Administer IV doses over 60 minutes to reduce bilirubin encephalopathy risk 10.
HIV-Infected Patients:
Use the same treatment regimens as HIV-negative patients 6.
Emerging Therapies
Zoliflodacin, a novel oral spiropyrimidinetrione, shows promise as a potential alternative with high cure rates for urogenital and rectal gonorrhea in Phase 3 trials, though it is not yet FDA-approved 11. This represents a critical development given the limited antimicrobial pipeline.